Goldenwell Biotech, Inc.
GWLL · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | -$0 |
| % Growth | -100% | – | 100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | -$0 |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | – | 100% | – | 53.8% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -8.3% | – | 12,111.4% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -13.9% | – | 17,427.8% |
| EPS | -0 | -0 | -0 | -0 |
| % Growth | 0% | 66.7% | 0% | – |
| EPS Diluted | -0 | -0 | -0 | -0 |
| Weighted Avg Shares Out | 96 | 97 | 99 | 99 |
| Weighted Avg Shares Out Dil | 96 | 96 | 99 | 99 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | -$0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -8.3% | – | 12,111.4% |